

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Cytokinetics UK (aficamten)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Arrhythmia Alliance	Board of Community Health Councils in
Atrial Fibrillation Association	Wales
Cardiomyopathy UK	British National Formulary
Cardiovascular Care Partnership	Care Quality Commission
Circulation Foundation	Department of Health - Northern Ireland
Gene People	Healthcare Improvement Scotland
Genetic Alliance UK	Medicines and Healthcare products
Haemochromatosis UK	Regulatory Agency
HEART UK	National Association of Primary Care
Pumping Marvellous	National Pharmacy Association
Somerville Foundation	NHS Wales Joint Commissioning
South Asian Health Foundation	Committee
Specialised Healthcare Alliance	NHS Confederation
·	Scottish Medicines Consortium
Healthcare professional groups	Welsh Government
 Association of Genetic Nurses and 	
Counsellors	Possible comparator companies
British Association for Nursing in	Bristol Myers Squibb (mavacamten)
Cardiovascular Care	
British Atherosclerosis Society	Relevant research groups
British Cardiovascular Intervention	British Society for Cardiovascular
Society	Research
British Cardiovascular Society	Genomics England
British Geriatrics Society	MRC Clinical Trials Unit
British Heart Foundation	National Centre for Cardiovascular
British Nuclear Cardiology Society	Preventions and Outcomes
British Society for Gene and Cell Therapy	National Institute for Health Research
British Society for Genetic Medicine	Associated Public Health groups
British Society for Heart Failure	Public Health Wales
British Society of Cardiovascular Imaging	UK Health Security Agency

Provisional stakeholder list for the evaluation of aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 National Heart and Lung Institute Primary Care Cardiovascular Society Royal College of General Practitioners Royal College of Nursing Royal College of Ophthalmologists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Cardiological Science and Technology Society for Vascular Technology of Great Britain and Ireland UK Clinical Pharmacy Association Vascular Society of Great Britain and Ireland 	
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.